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Abstract 
We exploited the dual positive effects of rapamycin to prevent GvHD and control ma-
lignant cells upon infusion of unmanipulated grafts from family haploidentical donors to 
patients affected by advanced hematological malignancies. Preliminary results on 45 pa-
tients show the feasibility of this platform with an appreciable low rate of GvHD. 
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The great interest in transplantation from hap-
loidentical donors arises from the immediate availa-
bility of a suitable one-haplotype mismatched donor 
for  virtually all  patients, particularly for those who 
urgently need a transplant. In the absence of a HLA 
full matched donor, alternative donors such as cord 
blood or haploidentical HSCT have been intensively 
investigated  in  the  past  decade1.  The  most  experi-
enced  transplantation  platform  has  been  the  T-cell 
depleted  grafts  with  high  cell  dose  of  CD34+  cells 
coming from family haploidentical donors. Progress 
have been made in the optimization of conditioning 
regimens and graft selection to allow a stable hema-
topoietic  engraftment  across  major  HLA-barriers, 
with promising leukemia-free survivals in adults with 
acute leukemias. The largest series has been reported 
by  the  Acute  Leukemia  Working  Party  registry  of 
EBMT; a CD34+ selected graft produced a high en-
graftment  rate,  minimal  GvHD  and  relevant  leuke-
mia-free  survival  was  reported  for  patients  trans-
planted in complete remission2. Unfortunately, trans-
plant-related  deaths  are  observed  in  a  significant 
proportion  of  recipients.  Leading  causes  of  deaths 
reported were infections and interstitial pneumonia: 
any further reduction in TRM will only be achieved 
by hastening post-transplant immune recovery. The 
group in Perugia has recently developed a strategy for 
transferring  donor  pathogen-specific  immune  re-
sponses safely across the HLA barrier3. Several addi-
tional strategies are currently exploring different cell 
therapy  approaches  aimed  at  improving 
post-transplant immune reconstitution while control-
ling GvHD: regulatory T cells4 and the add-back in-
fusions of donor lymphocytes genetically engineered 
with  the  herpes  simplex  virus-thymidine  kinase 
(HSV-TK) suicide gene5. A partial T-cell depletion can 
be  provided  by  alternative  selections,  such  as 
CD3/CD19 negative selection or selective depletion of 
alloreactive T-cells6; T-cell content of 1x105/kg in the 
graft requires a post-transplant immune prophylaxis 
and translates into a significant risk of acute GvHD.  
Recently,  new  platforms  for  haploidentical 
transplantation from unmanipulated graft have been 
developed7. We designed a clinical study investigat-
ing the feasibility of haploidentical SCT in the absence 
of ex-vivo T-cell depletion, addressing patients with 
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leukemias in advanced diseases. To this purpose, we 
selected  a  calcineurin  inhibitor-free  GvHD  prophy-
laxis  based  on  rapamycin,  mycophenolate  mofetil 
(MMF)  and  anti-T  lymphocytes  globulin 
(ATG-Fresenius),  in  the  attempt  to  promote  a  fast 
post-transplant immune recovery with a preferential 
accumulation of regulatory T cells (Tregs). Rapamycin 
is  an  immunosuppressive  drug  that,  in  contrast  to 
calcineurin  inhibitors,  promotes  the  generation  of 
natural  Tregs  in  murine  models.  Natural  Tregs  are 
cells endowed with suppressive activity, that does not 
require  previous  antigen  exposure  and  are  thus  at-
tractive candidates for the clinical modulation of ex-
cessive  immune  responses,  including autoimmunity 
and  transplantation  reactions.  In  mouse  models  of 
SCT, the adoptive transfer of purified natural Tregs 
has  been  shown  to  prevent  GvHD  while  sparing  a 
significant  graft-versus-leukemia  (GvL)  effect.  The 
infusion of Tregs after UCB8 and haploidentical SCT 
to prevent GvHD has produced promising results in 
recent clinical trials4. Besides its effects on Tregs, ra-
pamycin exerts a direct antineoplastic activity against 
different haematological malignancies. In our study, 
we exploited these dual positive effects of rapamycin 
to prevent GvHD and control malignant cells upon 
infusion  of  unmanipulated  grafts  from  family  hap-
loidentical  donors  to  patients  affected  by  advanced 
hematological malignancies. Preliminary results on 45 
patients show the feasibility of this platform with an 
appreciable low rate of GvHD. 
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